DNDN Stock News 1.94 05/09/2014 19:51:49 Dendreon Corp (DNDN
Post# of 273330
Posted On: 05/09/2014 8:51:55 PM
Dendreon Corp (DNDN) 1.94 $DNDN
Why Dendreon (DNDN) Stock Is Down Today
at The Street - Fri May 09, 3:10PM CDT
Shares of Dendreon (DNDN) continue to decline after the biotechnology company reported 2014 first quarter results.
Why Tesla Motors, Dendreon, and Intercept Pharmaceuticals Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Thu May 08, 7:35PM CDT
The stock market nixed hopes that it would rise to unprecedented highs on Thursday, but investors still fared relatively well, with the major market benchmarks delivering mixed results after giving up much larger gains earlier in the day. Yet certain...
Why Dendreon Corporation Shares Were Hammered
Sean Williams, The Motley Fool - Motley Fool - Thu May 08, 4:23PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Dendreon , a biopharmaceutical company...
Dendreon 1Q Earnings a Mixed Bag
Tamara Walsh, The Motley Fool - Motley Fool - Thu May 08, 8:32AM CDT
Dendreon reported fiscal 2014 first-quarter earnings results before the market opened today. The biotech company's results beat analyst estimates on the bottom line, but came up short on revenue. For the period ended March 31, Dendreon posted a...
Today's Top Health Care Stocks to Watch: Depomed Inc., Dendreon Corp., and Jazz Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Thu May 08, 8:00AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Depomed , Dendreon , and Jazz Pharmaceuticals . Depomed to report first-quarter earnings today The biopharma world will likely take a keen interest in...
Dendreon Announces First Quarter 2014 Results
Business Wire - Thu May 08, 6:30AM CDT
Dendreon Corporation (Nasdaq: DNDN) today reported results for the first quarter ended March 31, 2014. Net product revenue for the quarter was $68.8 million compared to $67.6 million in the first quarter of 2013. Net loss in the first quarter of 2014 was $36.4 million, or $0.24 per share, compared to a net loss of $72.0 million, or $0.48 per share for the same period in 2013. As of March 31, 2014, Dendreon had approximately $170 million in cash, cash equivalents, and short-term and long-term investments.
Cervical Cancer - Pipeline Review, H1 2014: 48 Company and 82 Drugs Profiled
M2 - Wed May 07, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wpfpds/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - 3SBio Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Amorfix Life Sciences Ltd. - Antigen Express, Inc. - ApoVax, Inc. - Arbor Vita Corporation - Azaya Therapeutics Incorporated - Bionor Pharma ASA - CEL-SCI Corporation - CZ BioMed Corp - Centre de Regulacio Genomica - Chong Kun Dang Pharmaceutical Corp. - Coridon Pty Ltd - Daiichi Sankyo Company, Limited - Dendreon Corporation - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Formune S.L. - Genetic Immunity, Inc - Genexine, Inc. - Genmab A/S - Genticel - Gilead Sciences, Inc. - GlaxoSmithKline plc - Helix BioPharma Corp. - ISA Pharmaceuticals B.V. - Indian Immunologicals Limited - LondonPharma Ltd - Med Discovery SA Drug Profiles: - hot water extract of mycobacterium tuberculosis - bevacizumab - (tegafur gimeracil oteracil potassium) - etirinotecan pegol - interferon alpha-2b - ADXS-HPV - ProCervix - hot water extract of mycobacterium tuberculosis - celecoxib - Triapine - exatecan mesylate - buparlisib hydrochloride - nimotuzumab - GSK-2141795 trametinib - TG-4001 - pazopanib hydrochloride - CIGB-228 Vaccine - CIGB-300 - nedaplatin [paclitaxel albumin-bound] - TA-HPV Vaccine - mapatumumab - artemether - HLA-A-0201 Restricted Specific Epitope Peptide Vaccine - ISA-101 - HuMax-TF ADC - PDS-0101 - docetaxel liposomal - Leukocyte Interleukin Injection - everolimus - GSK-2256098 For more information visit http://www.researchandmarkets.com/research/wp...cal_cancer
Should You Worry About the Short Interest in Dendreon (DNDN)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 07, 8:22AM CDT
Should You Worry About the Short Interest in Dendreon (DNDN)?
Pre-market Biotech Picks -- Research on Dendreon, Keryx Biopharma, Idera Pharma, and Vertex Pharma
PR Newswire - Wed May 07, 7:00AM CDT
The US markets saw a negative sentiment on Tuesday, May 6, 2014, with the NASDAQ Composite closing at 4,080.76, down 1.38%, the Dow Jones Industrial Average ending the session 0.78% lower at 16,401.02, and the S&P 500 edging 0.90% lower to finish the trading session at 1,867.72. The loss were broad based with nine out of the ten sectors finishing lower. The S&P 500 Health Care Sector Index ended the day at 666.48, down 0.91%, whereas the index has gained 4.08% in the previous three months. Investor-Edge has initiated coverage on the following equities: Dendreon Corporation (NASDAQ: DNDN), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Idera Pharmaceuticals Inc. (NASDAQ: IDRA) and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free technical research on DNDN, KERX, IDRA and VRTX can be downloaded upon signing up at:
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 30, 6:08PM CDT
I follow quite a lot of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
Dendreon to Host Conference Call on May 8 to Announce First Quarter Financial Results
Business Wire - Mon Apr 28, 3:01PM CDT
Dendreon Corporation (Nasdaq
NDN) today announced that management will host a conference call on Thursday, May 8, 2014 at 9:00 a.m. EST to review first quarter financial results.
Global Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/94xvzp/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - Johnson & Johnson - Sanofi - Novartis AG - AstraZeneca PLC - Astellas Pharma Inc. - Medivation, Inc. - Dendreon Corporation - Takeda Pharmaceutical Company Limited - Exelixis, Inc. - Bristol-Myers Squibb Company - National Cancer Institute - Duke University - The University of Texas M. D. Anderson Cancer Center - University of California, San Francisco - Swiss Group for Clinical Cancer Research - Barbara Ann Karmanos Cancer Institute - NCIC Clinical Trials Group - Memorial Sloan Kettering Cancer Center - University of Southern California For more information visit http://www.researchandmarkets.com/research/94xvzp/metastatic
Global Hormone-Sensitive Prostate Cancer Global Clinical Trials Review 2014 - Profiles of 16 Top Organisations
M2 - Thu Apr 17, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9m7lf5/hormonesensitive) has announced the addition of the "Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014 provides data on the Hormone-Sensitive Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone-Sensitive Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hormone-Sensitive Prostate Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies/Organisations Participating in Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials - Novartis AG - Ferring International Center S.A. - Johnson & Johnson - GlaxoSmithKline plc - Dendreon Corporation - CMX Research Inc. - National Cancer Institute - Massachusetts General Hospital - University of California, San Francisco - Azienda Provinciale per i Servizi Sanitari - Comprehensive Cancer Centers of Nevada - City of Hope National Medical Center - Oslo University Hospital - Keio University - Barbara Ann Karmanos Cancer Institute - University of Pennsylvania For more information visit http://www.researchandmarkets.com/research/9m...esensitive
Global Therapeutic Vaccines Market 2014-2018 with Agenus, Bavarian Nordic A/S, Dendreon, GSK & Novartis International Dominating
M2 - Wed Apr 16, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zb45f5/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. The Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. The increase in technological advances and improved understanding of immunology and immunotherapy has enabled the discovery of many biomarkers, thus aiding the development of therapy through the body's natural defense mechanism. Vaccines are usually thought of as biologics, which elicit an immune response to initiate a defense mechanism. This led to the development of therapeutic vaccines, which can induce the immune system to attack the targeted diseased tissue with greater bioavailability and specificity with minimal side effects. Various strategies have been developed to make therapeutic vaccines viable alternatives to the existing therapeutic approaches. Thus, improved understanding of immunology and immunotherapy is expected to boost the growth of the Global Therapeutic Vaccines market. According to the report, the incidence of cancers, infectious diseases, and physiological disorders is widespread owing to poor lifestyle, low immunity, and unhygienic conditions. As a result, the incidence of disorders such as Alzheimer's disease, Parkinson's disease, cancer, diabetes, and infectious diseases such as Hepatitis B, HIV/AIDS, and HPV is rising. The manifestation of these ailments is expected to increase due to a rise in aging population. The use of these vaccines to treat such ailments will be boosted by an increase in prevalence of these diseases and disorders, thus boosting the growth of the market. Further, the report states that the stringent government regulations could lead to delays in production and additional manufacturing costs. Vendors transfer the burden of the extra costs onto the end-users, making the adoption of the vaccines challenging. Key Vendors - Agenus Inc. - Bavarian Nordic A/S. - Dendreon Corp. - GlaxoSmithKline plc - Novartis International AG Other Prominent Vendors - AFFiRiS AG. - Argos Therapeutics Inc. - Celldex Therapeutics Inc. - CEL-SCI Corp. - Cytos Biotechnology AG - GlobeImmune Inc. - NewLink Genetics Corp. - NovaRx Corp. - Oncothyreon Inc. - TVAX Biomedical Inc. - TapImmune Inc. - Vical Inc. - Vaccinogen Inc. Market Drivers/Trends/Challenges - Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders - Ongoing Development of a Large Number of Therapeutic Vaccines - Stringent Regulations - Adverse Side Effects of Therapeutic Vaccines - Increase in Mergers and Acquisitions Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Pipeline Analysis - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zb45f5/global
5 Innovations Wall Street and Investors Don't Understand How to Value
Sean Williams, The Motley Fool - Motley Fool - Sun Apr 13, 10:31AM CDT
Innovation is the cornerstone to any successful business . From automakers and restaurants to mobile device makers and biotech companies, innovation is what separates one company from the next. It's also what drives revenue and profits for a company...
Immune Responses Enhanced and Sustained When PROVENGE(R) (sipuleucel-T) is Given After Androgen Deprivation Therapy in Biochemically-Recurrent Prostate Cancer
Business Wire - Fri Apr 11, 6:00AM CDT
April 11, 2014 - Dendreon Corporation (NASDAQ NDN) today announced the presentation of preliminary data from a long-term analysis of the Phase II STAND study demonstrating that tumor-specific T-cell responses appear to be enhanced and sustained when PROVENGE(R) (sipuleucel-T) is given after androgen deprivation therapy (ADT) in patients with biochemically-recurrent prostate cancer (BRPC) at high risk for metastases. These data will be presented at the 29th Annual European Association of Urology (EAU) Congress taking place from April 11-15, 2014 in Stockholm, Sweden.(1)
5 Biotechs With Prostate Cancer Treatments Worth Watching
George Budwell, The Motley Fool - Motley Fool - Sat Apr 05, 4:30PM CDT
In the United States, prostate cancer is now the most common type of malignancy detected in men. Even more concerning is that prostate cancer has crept up to the second-leading cause of cancer-specific deaths among men in the U.S., according to...
Why I Bought Exelixis
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 04, 11:05AM CDT
Some days as a biotech investor, no matter how savvy you think you are, you just have to bury your head in the sand because you're bound to experience a bad day. That's what happened last week to shareholders of Exelixis , a company I've been very...
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014
M2 - Wed Apr 02, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qc2v39/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Sanofi - Johnson & Johnson - Novartis AG - Astellas Pharma Inc. - Takeda Pharmaceutical Company Limited - Bristol-Myers Squibb Company - Bayer AG - Medivation, Inc. - AstraZeneca PLC - Dendreon Corporation Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - University of California, San Francisco - Memorial Sloan Kettering Cancer Center - Duke University - Barbara Ann Karmanos Cancer Institute - Swiss Group for Clinical Cancer Research - University of Wisconsin Madison - Stanford University For more information visit http://www.researchandmarkets.com/research/qc2v39/hormone
The Global Vaccine Market Forecast is Expected to Grow at a CAGR of around 12% during 2012-2017
M2 - Fri Mar 28, 10:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/87zbl9/global_vaccine) has announced the addition of the "Global Vaccine Market Forecast to 2017" report to their offering. Of late, the vaccines market is burgeoning with immense activities. Big pharmaceutical companies like GSK, Pfizer, Merck etc. are struggling to maintain their revenue and operating incomes amidst patent cliffs of blockbuster drugs. In such a scenario, vaccines, which have high entry barriers for generic players and the potential to generate blockbuster sales, are increasingly alluring the players. Besides, the market has also gained momentum due to the recent technological advances that now allow the manufacturing of high efficacy combination vaccines, providing protection from a plethora of diseases in one schedule. This has resulted in the introduction of several promising vaccines, actively promoted by health agencies and non-profit organizations to offer maximum immunization coverage, especially in the developing regions with high incidence rates of infectious diseases. In the report, the vaccine market has been studied on three distinct levels: Regional, Therapeutic Category, and Company. For regional analysis, key vaccine markets that together constitute around 90% of the global market, have been profiled. Further, the market has been broken down into 16 distinct therapeutic categories and their current and future outlook to 2017 has been analyzed. Through this, our analysts have conducted a thorough opportunity assessment in various therapeutic categories and regions to clearly highlight avenues which offer maximum opportunities for growth. Companies Mentioned: - AstraZeneca Plc. - Baxter International Inc. - BioCSL (CSL Biotherapies) - Crucell - Dendreon Corporation - Emergent Biosolutions - GSK - Merck - Novartis - Pfizer - Sanofi-Pasteur - Takeda Pharmaceutical Company Limited For more information visit http://www.researchandmarkets.com/research/87...al_vaccine About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Why Dendreon (DNDN) Stock Is Down Today
at The Street - Fri May 09, 3:10PM CDT
Shares of Dendreon (DNDN) continue to decline after the biotechnology company reported 2014 first quarter results.
Why Tesla Motors, Dendreon, and Intercept Pharmaceuticals Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Thu May 08, 7:35PM CDT
The stock market nixed hopes that it would rise to unprecedented highs on Thursday, but investors still fared relatively well, with the major market benchmarks delivering mixed results after giving up much larger gains earlier in the day. Yet certain...
Why Dendreon Corporation Shares Were Hammered
Sean Williams, The Motley Fool - Motley Fool - Thu May 08, 4:23PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Dendreon , a biopharmaceutical company...
Dendreon 1Q Earnings a Mixed Bag
Tamara Walsh, The Motley Fool - Motley Fool - Thu May 08, 8:32AM CDT
Dendreon reported fiscal 2014 first-quarter earnings results before the market opened today. The biotech company's results beat analyst estimates on the bottom line, but came up short on revenue. For the period ended March 31, Dendreon posted a...
Today's Top Health Care Stocks to Watch: Depomed Inc., Dendreon Corp., and Jazz Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Thu May 08, 8:00AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Depomed , Dendreon , and Jazz Pharmaceuticals . Depomed to report first-quarter earnings today The biopharma world will likely take a keen interest in...
Dendreon Announces First Quarter 2014 Results
Business Wire - Thu May 08, 6:30AM CDT
Dendreon Corporation (Nasdaq: DNDN) today reported results for the first quarter ended March 31, 2014. Net product revenue for the quarter was $68.8 million compared to $67.6 million in the first quarter of 2013. Net loss in the first quarter of 2014 was $36.4 million, or $0.24 per share, compared to a net loss of $72.0 million, or $0.48 per share for the same period in 2013. As of March 31, 2014, Dendreon had approximately $170 million in cash, cash equivalents, and short-term and long-term investments.
Cervical Cancer - Pipeline Review, H1 2014: 48 Company and 82 Drugs Profiled
M2 - Wed May 07, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wpfpds/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - 3SBio Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Amorfix Life Sciences Ltd. - Antigen Express, Inc. - ApoVax, Inc. - Arbor Vita Corporation - Azaya Therapeutics Incorporated - Bionor Pharma ASA - CEL-SCI Corporation - CZ BioMed Corp - Centre de Regulacio Genomica - Chong Kun Dang Pharmaceutical Corp. - Coridon Pty Ltd - Daiichi Sankyo Company, Limited - Dendreon Corporation - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Formune S.L. - Genetic Immunity, Inc - Genexine, Inc. - Genmab A/S - Genticel - Gilead Sciences, Inc. - GlaxoSmithKline plc - Helix BioPharma Corp. - ISA Pharmaceuticals B.V. - Indian Immunologicals Limited - LondonPharma Ltd - Med Discovery SA Drug Profiles: - hot water extract of mycobacterium tuberculosis - bevacizumab - (tegafur gimeracil oteracil potassium) - etirinotecan pegol - interferon alpha-2b - ADXS-HPV - ProCervix - hot water extract of mycobacterium tuberculosis - celecoxib - Triapine - exatecan mesylate - buparlisib hydrochloride - nimotuzumab - GSK-2141795 trametinib - TG-4001 - pazopanib hydrochloride - CIGB-228 Vaccine - CIGB-300 - nedaplatin [paclitaxel albumin-bound] - TA-HPV Vaccine - mapatumumab - artemether - HLA-A-0201 Restricted Specific Epitope Peptide Vaccine - ISA-101 - HuMax-TF ADC - PDS-0101 - docetaxel liposomal - Leukocyte Interleukin Injection - everolimus - GSK-2256098 For more information visit http://www.researchandmarkets.com/research/wp...cal_cancer
Should You Worry About the Short Interest in Dendreon (DNDN)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 07, 8:22AM CDT
Should You Worry About the Short Interest in Dendreon (DNDN)?
Pre-market Biotech Picks -- Research on Dendreon, Keryx Biopharma, Idera Pharma, and Vertex Pharma
PR Newswire - Wed May 07, 7:00AM CDT
The US markets saw a negative sentiment on Tuesday, May 6, 2014, with the NASDAQ Composite closing at 4,080.76, down 1.38%, the Dow Jones Industrial Average ending the session 0.78% lower at 16,401.02, and the S&P 500 edging 0.90% lower to finish the trading session at 1,867.72. The loss were broad based with nine out of the ten sectors finishing lower. The S&P 500 Health Care Sector Index ended the day at 666.48, down 0.91%, whereas the index has gained 4.08% in the previous three months. Investor-Edge has initiated coverage on the following equities: Dendreon Corporation (NASDAQ: DNDN), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Idera Pharmaceuticals Inc. (NASDAQ: IDRA) and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free technical research on DNDN, KERX, IDRA and VRTX can be downloaded upon signing up at:
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 30, 6:08PM CDT
I follow quite a lot of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
Dendreon to Host Conference Call on May 8 to Announce First Quarter Financial Results
Business Wire - Mon Apr 28, 3:01PM CDT
Dendreon Corporation (Nasdaq
NDN) today announced that management will host a conference call on Thursday, May 8, 2014 at 9:00 a.m. EST to review first quarter financial results. Global Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/94xvzp/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - Johnson & Johnson - Sanofi - Novartis AG - AstraZeneca PLC - Astellas Pharma Inc. - Medivation, Inc. - Dendreon Corporation - Takeda Pharmaceutical Company Limited - Exelixis, Inc. - Bristol-Myers Squibb Company - National Cancer Institute - Duke University - The University of Texas M. D. Anderson Cancer Center - University of California, San Francisco - Swiss Group for Clinical Cancer Research - Barbara Ann Karmanos Cancer Institute - NCIC Clinical Trials Group - Memorial Sloan Kettering Cancer Center - University of Southern California For more information visit http://www.researchandmarkets.com/research/94xvzp/metastatic
Global Hormone-Sensitive Prostate Cancer Global Clinical Trials Review 2014 - Profiles of 16 Top Organisations
M2 - Thu Apr 17, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9m7lf5/hormonesensitive) has announced the addition of the "Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014 provides data on the Hormone-Sensitive Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone-Sensitive Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hormone-Sensitive Prostate Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies/Organisations Participating in Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials - Novartis AG - Ferring International Center S.A. - Johnson & Johnson - GlaxoSmithKline plc - Dendreon Corporation - CMX Research Inc. - National Cancer Institute - Massachusetts General Hospital - University of California, San Francisco - Azienda Provinciale per i Servizi Sanitari - Comprehensive Cancer Centers of Nevada - City of Hope National Medical Center - Oslo University Hospital - Keio University - Barbara Ann Karmanos Cancer Institute - University of Pennsylvania For more information visit http://www.researchandmarkets.com/research/9m...esensitive
Global Therapeutic Vaccines Market 2014-2018 with Agenus, Bavarian Nordic A/S, Dendreon, GSK & Novartis International Dominating
M2 - Wed Apr 16, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zb45f5/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. The Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. The increase in technological advances and improved understanding of immunology and immunotherapy has enabled the discovery of many biomarkers, thus aiding the development of therapy through the body's natural defense mechanism. Vaccines are usually thought of as biologics, which elicit an immune response to initiate a defense mechanism. This led to the development of therapeutic vaccines, which can induce the immune system to attack the targeted diseased tissue with greater bioavailability and specificity with minimal side effects. Various strategies have been developed to make therapeutic vaccines viable alternatives to the existing therapeutic approaches. Thus, improved understanding of immunology and immunotherapy is expected to boost the growth of the Global Therapeutic Vaccines market. According to the report, the incidence of cancers, infectious diseases, and physiological disorders is widespread owing to poor lifestyle, low immunity, and unhygienic conditions. As a result, the incidence of disorders such as Alzheimer's disease, Parkinson's disease, cancer, diabetes, and infectious diseases such as Hepatitis B, HIV/AIDS, and HPV is rising. The manifestation of these ailments is expected to increase due to a rise in aging population. The use of these vaccines to treat such ailments will be boosted by an increase in prevalence of these diseases and disorders, thus boosting the growth of the market. Further, the report states that the stringent government regulations could lead to delays in production and additional manufacturing costs. Vendors transfer the burden of the extra costs onto the end-users, making the adoption of the vaccines challenging. Key Vendors - Agenus Inc. - Bavarian Nordic A/S. - Dendreon Corp. - GlaxoSmithKline plc - Novartis International AG Other Prominent Vendors - AFFiRiS AG. - Argos Therapeutics Inc. - Celldex Therapeutics Inc. - CEL-SCI Corp. - Cytos Biotechnology AG - GlobeImmune Inc. - NewLink Genetics Corp. - NovaRx Corp. - Oncothyreon Inc. - TVAX Biomedical Inc. - TapImmune Inc. - Vical Inc. - Vaccinogen Inc. Market Drivers/Trends/Challenges - Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders - Ongoing Development of a Large Number of Therapeutic Vaccines - Stringent Regulations - Adverse Side Effects of Therapeutic Vaccines - Increase in Mergers and Acquisitions Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Pipeline Analysis - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zb45f5/global
5 Innovations Wall Street and Investors Don't Understand How to Value
Sean Williams, The Motley Fool - Motley Fool - Sun Apr 13, 10:31AM CDT
Innovation is the cornerstone to any successful business . From automakers and restaurants to mobile device makers and biotech companies, innovation is what separates one company from the next. It's also what drives revenue and profits for a company...
Immune Responses Enhanced and Sustained When PROVENGE(R) (sipuleucel-T) is Given After Androgen Deprivation Therapy in Biochemically-Recurrent Prostate Cancer
Business Wire - Fri Apr 11, 6:00AM CDT
April 11, 2014 - Dendreon Corporation (NASDAQ
NDN) today announced the presentation of preliminary data from a long-term analysis of the Phase II STAND study demonstrating that tumor-specific T-cell responses appear to be enhanced and sustained when PROVENGE(R) (sipuleucel-T) is given after androgen deprivation therapy (ADT) in patients with biochemically-recurrent prostate cancer (BRPC) at high risk for metastases. These data will be presented at the 29th Annual European Association of Urology (EAU) Congress taking place from April 11-15, 2014 in Stockholm, Sweden.(1) 5 Biotechs With Prostate Cancer Treatments Worth Watching
George Budwell, The Motley Fool - Motley Fool - Sat Apr 05, 4:30PM CDT
In the United States, prostate cancer is now the most common type of malignancy detected in men. Even more concerning is that prostate cancer has crept up to the second-leading cause of cancer-specific deaths among men in the U.S., according to...
Why I Bought Exelixis
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 04, 11:05AM CDT
Some days as a biotech investor, no matter how savvy you think you are, you just have to bury your head in the sand because you're bound to experience a bad day. That's what happened last week to shareholders of Exelixis , a company I've been very...
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014
M2 - Wed Apr 02, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qc2v39/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Sanofi - Johnson & Johnson - Novartis AG - Astellas Pharma Inc. - Takeda Pharmaceutical Company Limited - Bristol-Myers Squibb Company - Bayer AG - Medivation, Inc. - AstraZeneca PLC - Dendreon Corporation Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - University of California, San Francisco - Memorial Sloan Kettering Cancer Center - Duke University - Barbara Ann Karmanos Cancer Institute - Swiss Group for Clinical Cancer Research - University of Wisconsin Madison - Stanford University For more information visit http://www.researchandmarkets.com/research/qc2v39/hormone
The Global Vaccine Market Forecast is Expected to Grow at a CAGR of around 12% during 2012-2017
M2 - Fri Mar 28, 10:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/87zbl9/global_vaccine) has announced the addition of the "Global Vaccine Market Forecast to 2017" report to their offering. Of late, the vaccines market is burgeoning with immense activities. Big pharmaceutical companies like GSK, Pfizer, Merck etc. are struggling to maintain their revenue and operating incomes amidst patent cliffs of blockbuster drugs. In such a scenario, vaccines, which have high entry barriers for generic players and the potential to generate blockbuster sales, are increasingly alluring the players. Besides, the market has also gained momentum due to the recent technological advances that now allow the manufacturing of high efficacy combination vaccines, providing protection from a plethora of diseases in one schedule. This has resulted in the introduction of several promising vaccines, actively promoted by health agencies and non-profit organizations to offer maximum immunization coverage, especially in the developing regions with high incidence rates of infectious diseases. In the report, the vaccine market has been studied on three distinct levels: Regional, Therapeutic Category, and Company. For regional analysis, key vaccine markets that together constitute around 90% of the global market, have been profiled. Further, the market has been broken down into 16 distinct therapeutic categories and their current and future outlook to 2017 has been analyzed. Through this, our analysts have conducted a thorough opportunity assessment in various therapeutic categories and regions to clearly highlight avenues which offer maximum opportunities for growth. Companies Mentioned: - AstraZeneca Plc. - Baxter International Inc. - BioCSL (CSL Biotherapies) - Crucell - Dendreon Corporation - Emergent Biosolutions - GSK - Merck - Novartis - Pfizer - Sanofi-Pasteur - Takeda Pharmaceutical Company Limited For more information visit http://www.researchandmarkets.com/research/87...al_vaccine About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
(0)
(0)